Table 2.

Frequency of chemotherapy regimens and type of malignancies in both intervention and control groups.

Treatment regimen,	Melatonin group (N = 36) N (%)	Control group (N = 30) N (%)	P-value
Cisplatin	11 (30.6)	9 (30)	0.06
Gemcitabine-cisplatin	2 (5.6)	2 (6.7)
Gemcitabine-dexamethasone-Cisplatin	5 (13.9)	6 (20)
Docetaxel-cisplatin-fluorouracil	7 (19.4)	2 (6.7)
Fluorouracil-cisplatin	2 (5.6)	1 (3.3)
Vinorelbine-cisplatin	0	1 (3.3)
Gemcitabine-cisplatin-rituximab	0	1 (3.3)
Cetuximab-cisplatin	0	1 (3.3)
Doxorubicin-cisplatin	0	1 (3.3)
Doxorubicin-fluorouracil-cisplatin	2 (5.6)	1 (3.3)
Etoposide-cisplatin	5 (13.9)	0
Docetaxel-cisplatin	2 (5.6)	1 (3.3)
Rituximab-etoposide-methylprednisolone-cytarabine-cisplatin	0	2 (6.7)
Docetaxel-cisplatin-fluorouracil	0	2 (6.7)
Malignancy types,			0.13
Lung cancer	6 (16.7)	3 (10)
Gastrointestinal cancer	5 (13.9)	3 (10)
Hodgkin lymphoma	4 (11.1)	10 (33.3)
Head and neck	12 (33.3)	7 (23.3)
Urogenital cancer	5 (13.9)	5 (16.7)
Sarcoma	4 (11.1)	2 (6.7)